stockrowAmylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.
- Revenue
- −100.6%
- EPS
- +15.2%
- Free cash flow
- −24.5%
Quarter to June 2026, against a year earlier
Follow AMLX
Alert me
Amylyx Pharmaceuticals, Inc. (AMLX) P/S ratio
As of 5 November 2026, Amylyx Pharmaceuticals, Inc. (AMLX) trades at a P/S ratio of 35.4×. Over the past ten years it has ranged from 0.0× (March 2023) to 50.5× (August 2026); the current reading is higher than 96% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.1× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2024 | 2.9× | 11.54% |
| FY2023 | 2.6× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Dec 2024 | 2.9× | 162.57% |
| Sep 2024 | 1.1× | 162.28% |
| Jun 2024 | 0.4× | (7.34%) |
| Mar 2024 | 0.5× | (82.52%) |
| 7 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | n/m |
| PRGO Perrigo Company plc compare | 0.5× |
| PBH Prestige Consumer Healthcare Inc. compare | 1.8× |
| TRLV Trulieve Cannabis Corp. compare | 2.0× |
| HIMS Hims & Hers Health, Inc. compare | 2.2× |
| SUPN Indivior Pharmaceuticals Inc. compare | 2.4× |
| LQDA Liquidia Corporation compare | 8.8× |
| AMLX Amylyx Pharmaceuticals, Inc. | 35.4× |
| RGC Regencell Bioscience Holdings Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 2.1× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on AMLX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement